Numerous studies have unveiled KRAS, BRAF, IDH1/2, FGFR2, and EGFR as prevalent oncogenic drivers in CCA [5], especially the KRAS mutations, which might be one of the most frequent molecular alterations in iCCA [6]. This evidence concerns the gene KRAS and cholangiocarcinoma.